• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,502.12 579.48
( 0.75%)
Global Indices
Nasdaq
52,333.78 -6.42
(-0.01%)
Dow Jones
7,505.37 -14.99
(-0.20%)
Hang Seng
68,854.54 -1,620.42
(-2.30%)
Nikkei 225
10,484.10 -13.02
(-0.12%)
Forex
USD-INR
94.60 0.11
(0.12%)
EUR-INR
107.91 0.13
(0.12%)
GBP-INR
125.27 0.26
(0.21%)
JPY-INR
0.58 0.00
(-0.20%)

EQUITY - MARKET SCREENER

ARC Finance Ltd
Industry :  Finance & Investments
BSE Code
ISIN Demat
Book Value()
540135
INE202R01026
1.1352825
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
53
46.19
EPS(TTM)
Face Value()
Div & Yield %
0.01
1
0
 

axis bank ltd
Lupin receives EMA approval for Pediatric Indication of NaMuscla
Jul 01,2026
Lupin today announced that the European Medicines Agency (EMA) has approved a change to the terms of marketing authorization for NaMuscla, supported by the Pediatric Investigation Plan (PIP). The approval includes two new dosage strengths, 62 mg and 83 mg capsules, in addition to the existing 167 mg, and the revised indications that cover symptomatic treatment of myotonia in children (6¨C11 years, weighing at least 20 kg), adolescents (12¨C17 years), and adults (¡Ý18 years) with non-dystrophic myotonic disorder.